Combined goserelin and tamoxifen in premenopausal advanced breast cancer: duration of response and survival.

[1]  R. Blamey,et al.  Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer. , 1989, European journal of cancer & clinical oncology.

[2]  M. Williams,et al.  Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer. , 1986, The Journal of endocrinology.

[3]  A. Howell,et al.  A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Williams,et al.  The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. , 1986, British Journal of Cancer.

[5]  M. Williams,et al.  Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. , 1985, Journal of steroid biochemistry.

[6]  M. Beksaç,et al.  The endocrinological evaluation of bilateral and unilateral oophorectomy in premenopausal women. , 1983, International journal of fertility.

[7]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[8]  E. Benson.  Assessment of response to treatment in advanced breast cancer. British Breast Group. , 1974, Lancet.

[9]  Elisa T. Lee,et al.  A computer program for comparing K samples with right-censored data. , 1972, Computer programs in biomedicine.